Pekka Sillanaukee (born 1964, TampereFinland) is a Finnish health technology entrepreneur.[1] Pekka graduated as an organic chemist in 1989, he became a Ph.D. in 1992 and was appointed Docent of Medical Biochemistry at the Faculty of Medicine of the University of Tampere in 1993. Pekka has been a co-author of approximately 120 scientific original articles,[2] reviews or summaries. His scientific work has focused on clinical and medical biochemistry, alcohol, brain and cardiovascular related diseases, and development of laboratory-diagnostic tests and processes. He also has four international patents.[3][4][5][6]
Pekka has worked as a researcher at the Medical School of the University of Tampere and at Tampere University Hospital, as a responsible clinical researcher at Alko's research laboratories from 1987 to 1993, then as a director and business unit member at Pharmacia & Upjohn Inc. (Pfizer) 1994–1999, CEO at FIT Biotech Plc 1999–2004, and thereafter as an entrepreneur, co-founder or co-owner of different Finnish, Swedish and Estonian health technology and service companies including Bioretec Ltd, ESO International Ltd, Innokas Medical Ltd, Nordic Senior Services Ltd, Nova Vita Ltd, OS-Service, Ovumia Ltd, Palvelutähti Ltd, Paavolankoti Ltd, and Quattromed Ltd.
Since 2014 Sillanaukee has focused on the development of fertility treatment technologies and practices in Ovumia Fertility Clinic.[7]
Assistant Professorship (docent) of Medical Biochemistry, Medical Faculty, University of Tampere, Tampere, 1993. Qualification for Assistant Professorship (docent) in Karolinska Institute, Stockholm, Sweden, 1998.
^ abEP 0765476B1, Ola Martensson, Kaija SEPPÄ, Pekka Sillanaukee, "The use of sialic acid determination for determining alcohol consumption", published 1995-06-07, assigned to Axis-Shield Asa
^US 6054322, Pekka Sillanaukee, Kaija Seppa, Ola Mårtensson, "Use of sialic acid determination for determining alcohol consumption", published 1995-06-07, assigned to Axis-Shield Asa